focus -WSS

focus

author：fashion 2025-09-29 19:06:10 - browse：478

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： As pharma fights Medicare drug negotiation, hospitals, docs silent

explore

focus

WSS

Radiation, mainstay of cancer treatment, begins a fade

Complete sequence of Y chromosome published for first time

Can food be medicine? And other questions about a new push

As pharma fights Medicare drug negotiation, hospitals, docs silent

Grail is spending more than ever lobbying Congress

Meta looks to target Twitter with a rival app called Threads

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Medicare explains how it will choose drugs for negotiation

Apple is now the first public company to be valued at $3 trillion

Bacterial infection may be ‘key event’ in endometriosis, study says

Tori Bowie and the unacceptable rates of Black maternal death

How to make AI work for medicine

What does generative AI mean for health care? We asked experts

Inside the fall of star MIT scientist David Sabatini

BioMarin wins approval for gene therapy to treat hemophilia A

Why is France rioting? What to know about the fatal police shooting of Nahel M

explore

Apellis safety probe of eye disease drug centers on injection needle

A new study asks: Are we harming blood donors by taking blood?

Doctor appointment wait times are getting worse

Feds fine Medicare Advantage plans for overcharging members

New case study details death in closely watched Alzhiemer's trial

PhRMA sues HHS over Medicare drug price negotiation

explore

focus

entertainment

explore